Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 8/20 | 0.58 |
| ▸ | NTSR1 | P30989 | 8/20 | 0.58 |
| ▸ | SORT1 | Q99523 | 8/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.55 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31410880 | 0.97 | OPRM1 (0.58) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL31676699 | 0.94 | OPRM1 (0.57) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL30038002 | 0.94 | NPY4R (0.59) | OPRM1OPRD1NPFFR1NPFFR2 | |
| SCHEMBL30610291 | 0.92 | NMUR2 (0.59) | OPRM1OPRD1SLC6A2NPFFR1NPFFR2 | |
| SCHEMBL31676697 | 0.91 | OPRM1 (0.59) | OPRM1OPRD1NPFFR1NPFFR2 | |
| SCHEMBL29548698 | 0.91 | OPRM1 (0.55) | OPRM1OPRD1NPFFR1NPFFR2 | |
| SCHEMBL29496918 | 0.91 | SLC6A2 (0.57) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL29496917 | 0.91 | SLC6A2 (0.57) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL29769812 | 0.90 | EPHA2 (0.56) | NTSR2NTSR1OPRM1OPRD1SLC6A2 | |
| SCHEMBL29886800 | 0.90 | NTSR2 (0.67) | NTSR2NTSR1SORT1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021061-A1 | ARIADNE AND ANALOGS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROMUSCLAR DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021061-A1 | ARIADNE AND ANALOGS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROMUSCLAR DISORDERS | ATXN2, HCRTR2, CDR2 | NTSR2 86/4885NTSR1 240/4885SORT1 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.